Sunitinib in Patients With Breast Cancer With
Document Type
Article
Publication Date
2-1-2024
Original Citation
Calfa C,
Rothe M,
Mangat P,
Garrett-Mayer E,
Ahn E,
Burness M,
Gogineni K,
Rohatgi N,
Al Baghdadi T,
Conlin A,
Gaba A,
Hamid O,
Krishnamurthy J,
Gavini N,
Gold P,
Rodon J,
Rueter J,
Thota R,
Grantham G,
Hinshaw D,
Gregory A,
Halabi S,
Schilsky R.
Sunitinib in Patients With Breast Cancer With JCO Precis Oncol. 2024;8(8):e2300513
Keywords
JMG, Humans, Female, Sunitinib, Breast Neoplasms, Antineoplastic Agents, Mutation, Progression-Free Survival, Receptor, Fibroblast Growth Factor, Type 2, Receptor, Fibroblast Growth Factor, Type 1
JAX Source
JCO Precis Oncol. 2024;8(8):e2300513
ISSN
2473-4284
PMID
38354330
DOI
https://doi.org/10.1200/po.23.00513
Abstract
PURPOSE: The Targeted Agent and Profiling Utilization Registry Study is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations known to be drug targets. Results from cohorts of patients with metastatic breast cancer (BC) with
METHODS: Eligible patients had measurable disease, Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, and no standard treatment options. Simon's two-stage design was used with a primary end point of disease control (DC), defined as objective response (OR) or stable disease of at least 16 weeks duration (SD16+) according to RECIST v1.1. Secondary end points included OR, progression-free survival, overall survival, duration of response, duration of stable disease, and safety.
RESULTS: Forty patients with BC with
CONCLUSION: Sunitinib did not meet prespecified criteria to declare a signal of antitumor activity in patients with BC with either